(Q34572884)

3 August 2017

title

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis (English)

1 reference

3 August 2017

0 references

hepatocellular carcinoma

1 reference

15

Josep M Llovet

1 reference

3 August 2017

Vincenzo Mazzaferro

1

1 reference

3 August 2017

Raffaele Romito

2

1 reference

3 August 2017

Marcello Schiavo

3

1 reference

3 August 2017

Luigi Mariani

4

1 reference

3 August 2017

Tiziana Camerini

5

1 reference

3 August 2017

Sherrie Bhoori

6

1 reference

3 August 2017

Lorenzo Capussotti

7

1 reference

3 August 2017

Fulvio Calise

8

1 reference

3 August 2017

Riccardo Pellicci

9

1 reference

3 August 2017

Giulio Belli

10

1 reference

3 August 2017

Alessandro Tagger

11

1 reference

3 August 2017

Massimo Colombo

12

1 reference

3 August 2017

Ferruccio Bonino

13

1 reference

3 August 2017

Pietro Majno

14

1 reference

3 August 2017

HCC Italian Task Force

16

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

3 August 2017

1 reference

3 August 2017

volume

44

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

1543-1554

1 reference

Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial

3 August 2017

cites work

1 reference

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update

21 January 2018

1 reference

7 January 2021

Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy

1 reference

7 January 2021

Prevention of hepatocellular carcinoma

1 reference

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

7 January 2021

Resection and liver transplantation for hepatocellular carcinoma.

1 reference

7 January 2021

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

1 reference

7 January 2021

Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma

1 reference

7 January 2021

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

1 reference

7 January 2021

Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors

1 reference

7 January 2021

Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy

1 reference

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

7 January 2021

Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

7 January 2021

Management of hepatocellular carcinoma

1 reference

7 January 2021

Unbiased assessment of treatment effects on disease recurrence and survival in clinical trials

1 reference

7 January 2021

Applications of crude incidence curves

1 reference

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

7 January 2021

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

7 January 2021

Long-term course of interferon-treated chronic hepatitis C.

1 reference

7 January 2021

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

7 January 2021

Prevention of hepatitis C virus-related hepatocellular carcinoma

1 reference

7 January 2021

HCV natural history: the retrospective and prospective in perspective

1 reference

7 January 2021

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

1 reference

7 January 2021

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

7 January 2021

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

7 January 2021

Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey

1 reference

7 January 2021

Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis

1 reference

7 January 2021

Molecular pathogenesis of human hepatocellular carcinoma

1 reference

7 January 2021

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

1 reference

7 January 2021

Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs

1 reference

7 January 2021

Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21415

1 reference

3 August 2017

1 reference